Neurobehavioral Effects of Interferon-α in Patients with Hepatitis-C: Symptom Dimensions and Responsiveness to Paroxetine (original) (raw)

• Ambermoon P, Carter A, Hall WD, Dissanayaka NN, O’Sullivan JD (2011). Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction 106: 283–293.
  Article PubMed Google Scholar
• American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV 4th edn American Psychiatric Association: Washington, DC.
• Auyeung SF, Long Q, Royster EB, Murthy S, McNutt MD, Lawson DH et al (2009). Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy. Clin Trials 6: 480–490.
  Article PubMed PubMed Central Google Scholar
• Bagaglio S, Cinque P, Racca S, Pedale R, Grasso MA, Lazzarin A et al (2005). Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients. AIDS 19 (Suppl 3): S151–S165.
  Article PubMed Google Scholar
• Bender CM, Ergyn FS, Rosenzweig MQ, Cohen SM, Sereika SM (2005). Symptom clusters in breast cancer across 3 phases of the disease. Cancer Nurs 28: 219–225.
  Article PubMed Google Scholar
• Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M et al (2002). Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 22: 86–90.
  Article CAS PubMed Google Scholar
• Bull SJ, Huezo-Diaz P, Binder EB, Cubells JF, Ranjith G, Maddock C et al (2009). Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 14: 1095–1104.
  Article CAS PubMed Google Scholar
• Capuron L, Miller AH (2004). Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 56: 819–824.
  Article CAS PubMed Google Scholar
• Capuron L, Ravaud A, Dantzer R (2000). Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 18: 2143–2151.
  Article CAS PubMed Google Scholar
• Centers for Disease Control and Prevention (2011). Hepatitis C information for health professionals. http://www.cdc.gov/hepatitis/HCV/index.htm.
• Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM et al (1997). Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 19: 237–244.
  Article CAS PubMed Google Scholar
• Chen ML, Tseng HC (2006). Symptom clusters in cancer patients. Support Care Cancer 14: 825–830.
  Article PubMed Google Scholar
• Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J et al (2005). Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 66: 1050–1057.
  Article CAS PubMed Google Scholar
• DiMatteo MR, Lepper HS, Croghan TW (2000). Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160: 2101–2107.
  Article CAS PubMed Google Scholar
• Dodd MJ, Miaskowski C, Paul SM (2001). Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum 28: 465–470.
  CAS PubMed Google Scholar
• Folstein MF, Folstein SE, McHugh A (1975). ‘Mini-Mental State’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198.
  Article CAS PubMed Google Scholar
• Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J et al (2002). Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 35: 433–439.
  Article PubMed Google Scholar
• Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401.
  Article CAS PubMed Google Scholar
• Gift AG, Stommel M, Jablonski A, Given W (2003). A cluster of symptoms over time in patients with lung cancer. Nurs Res 52: 393–400.
  Article PubMed Google Scholar
• Giosue S, Casarini M, Ameglio F, Zangrilli P, Palla M, Altieri AM et al (2000). Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 11: 99–104.
  CAS PubMed Google Scholar
• Guillemin GJ, Wang L, Brew BJ (2005). Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation 2: 16.
  Article PubMed PubMed Central CAS Google Scholar
• Hammond MF (1998). Rating depression severity in the elderly physically ill patient: reliability and factor structure of the Hamilton and the Montgomery–Asberg depression rating scales. Int J Geriatr Psychiatry 13: 257–261.
  Article CAS PubMed Google Scholar
• Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J et al (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 7: 942–947.
  Article CAS PubMed Google Scholar
• Haward LR (1979). Multivariate symptom analysis related to response to lorazepam treatment. Curr Med Res Opin 6: 20–23.
  Article CAS PubMed Google Scholar
• Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E (2001). Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 96: 157–164.
  CAS PubMed Google Scholar
• Horikawa N, Yamazaki T, Sagawa M, Nagata T (1999). A case of akathisia during interferon-alpha therapy for chronic hepatitis type C. Gen Hosp Psychiatry 21: 134–135.
  Article CAS PubMed Google Scholar
• Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H (2000). Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 54: 565–572.
  Article CAS PubMed Google Scholar
• Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T (2000). Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 10: 129–132.
  Article CAS PubMed Google Scholar
• Kearns NP, Cruickshank CA, McGuigan KJ, Riley SA, Shaw SP, Snaith RP (1982). A comparison of depression rating scales. Br J Psychiatry 141: 45–49.
  Article CAS PubMed Google Scholar
• Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, Johnson RW et al (2003). Cytokine-induced sickness behavior. Brain Behav Immun 17 (Suppl 1): S112–S118.
  Article CAS PubMed Google Scholar
• Khan A, Brodhead AE, Kolts RL (2004). Relative sensitivity of the Montgomery–Asberg depression rating scale, the Hamilton depression rating scale and the clinical global impressions rating scale in antidepressant clinical trials: a replication analysis. Int Clin Psychopharmacol 19: 157–160.
  Article PubMed Google Scholar
• Kim HJ, McGuire DB, Tulman L, Barsevick AM (2005). Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs 28: 270–282.
  PubMed Google Scholar
• Kirkova J, Walsh D (2007). Cancer symptom clusters—a dynamic construct. Support Care Cancer 15: 1011–1013.
  Article PubMed Google Scholar
• Kirkova J, Walsh D, Aktas A, Davis MP (2010). Cancer symptom clusters: old concept but new data. Am J Hosp Palliat Care 27: 282–288.
  Article PubMed Google Scholar
• Kraus MR, Schafer A, Csef H, Faller H, Mork H, Scheurlen M (2001). Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci 46: 2060–2065.
  Article CAS PubMed Google Scholar
• Kumai T, Tateishi T, Tanaka M, Watanabe M, Shimizu H, Kobayashi S (2000). Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats. Life Sci 67: 663–669.
  Article CAS PubMed Google Scholar
• Lang CA, Conrad S, Garrett L, Battistutta D, Cooksley WG, Dunne MP et al (2006). Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage 31: 335–344.
  Article PubMed Google Scholar
• Laskus T, Radkowski M, Bednarska A, Wilkinson J, Adair D, Nowicki M et al (2002). Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol 76: 10064–10068.
  Article CAS PubMed PubMed Central Google Scholar
• Lindsay KL (1997). Therapy of hepatitis C: overview. Hepatology 26 (3 Suppl 1): 71S–77S.
  Article CAS PubMed Google Scholar
• Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P (2008). Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett 430: 264–268.
  Article CAS PubMed Google Scholar
• Lotrich FE, Loftis JM, Ferrell RE, Rabinovitz M, Hauser P (2011). IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interferon Cytokine Res 31: 331–336.
  Article CAS PubMed PubMed Central Google Scholar
• Maggi F, Giorgi M, Fornai C, Morrica A, Vatteroni ML, Pistello M et al (1999). Detection and quasispecies analysis of hepatitis C virus in the cerebrospinal fluid of infected patients. J Neurovirol 5: 319–323.
  Article CAS PubMed Google Scholar
• Mahrer AR, Mason DJ, Rosenshine M (1966). A headache syndrome in psychiatric patients: symptom clusters accompanying headaches. J Clin Psychol 22: 411–414.
  Article CAS PubMed Google Scholar
• Manesis EK, Hadziyannis SJ (2001). Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121: 101–109.
  Article CAS PubMed Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485–1492.
  Article CAS PubMed Google Scholar
• Miaskowski C, Dodd M, Lee K (2004). Symptom clusters: the new frontier in symptom management research. J Natl Cancer Inst Monogr 32: 17–21.
  Article Google Scholar
• Miller AH (2009). Norman cousins lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 23: 149–158.
  Article CAS PubMed Google Scholar
• Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389.
  Article CAS PubMed Google Scholar
• Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B et al (2010). Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics 51: 401–408.
  Article CAS PubMed PubMed Central Google Scholar
• Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P (2007). A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 103: 83–90.
  Article CAS PubMed Google Scholar
• Morsica G, Bernardi MT, Novati R, Uberti Foppa C, Castagna A, Lazzarin A (1997). Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients. J Med Virol 53: 252–254.
  Article CAS PubMed Google Scholar
• Murray J, Fishman SL, Ryan E, Eng FJ, Walewski JL, Branch AD et al (2008). Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol 14: 17–27.
  Article CAS PubMed PubMed Central Google Scholar
• O’Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N et al (2009). Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14: 511–522.
  Article CAS PubMed Google Scholar
• Oxenkrug G, Perianayagam M, Mikolich D, Requintina P, Shick L, Ruthazer R et al (2011). Interferon-gamma (+874) T/A genotypes and risk of IFN-alpha-induced depression. J Neural Transm 118: 271–274.
  Article CAS PubMed Google Scholar
• Pemberton LA, Kerr SJ, Smythe G, Brew BJ (1997). Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J Interferon Cytokine Res 17: 589–595.
  Article CAS PubMed Google Scholar
• Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al (1998). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks vs interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352: 1426–1432.
  Article CAS PubMed Google Scholar
• Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM et al (2005a). Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 66: 41–48.
  Article CAS PubMed PubMed Central Google Scholar
• Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ et al (2005b). Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 19: 23–27.
  Article CAS PubMed Google Scholar
• Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G et al (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15: 393–403.
  Article CAS PubMed Google Scholar
• Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP et al (2007). Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharm Therapeutics 25: 1163–1174.
  Article CAS Google Scholar
• Rubin DB (1976). Inference and missing data. Biometrika 63: 581–592.
  Article Google Scholar
• Schaefer M, Schwaiger M, Pich M, Lieb K, Heinz A (2003). Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 36 (Suppl 3): S203–S206.
  CAS PubMed Google Scholar
• Serretti A, Mandelli L (2010). Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 71: 1259–1272.
  Article PubMed Google Scholar
• Seyam MS, Freshwater DA, O’Donnell K, Mutimer DJ (2005). Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*. J Viral Hepat 12: 531–535.
  Article CAS PubMed Google Scholar
• Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R (1997). Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 747: 348–351.
  Article CAS PubMed Google Scholar
• Su KP, Huang SY, Peng CY, Lai HC, Huang CL, Chen YC et al (2010). Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry 67: 550–557.
  Article CAS PubMed Google Scholar
• Sunami M, Nishikawa T, Yorogi A, Shimoda M (2000). Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha. Clin Neuropharmacol 23: 59–61.
  Article CAS PubMed Google Scholar
• Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU (1991). Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114: 532–538.
  Article CAS PubMed Google Scholar
• Teva Pharmaceuticals USA Inc. (2011). Paroxetine. http://www.drugs.com/pro/paroxetine.html.
• Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P (1998). Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25 (Suppl 1): 39–47.
  CAS PubMed Google Scholar
• Vargas HE, Laskus T, Radkowski M, Wilkinson J, Balan V, Douglas DD et al (2002). Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transpl 8: 1014–1019.
  Article PubMed Google Scholar
• Vecsei L, Beal MF (1990). Influence of kynurenine treatment on open-field activity, elevated plus-maze, avoidance behaviors and seizures in rats. Pharmacol Biochem Behav 37: 71–76.
  Article CAS PubMed Google Scholar
• Walsh D, Donnelly S, Rybicki L (2000). The symptoms of advanced cancer: relationship to age, gender, and performance status in 1000 patients. Support Care Cancer 8: 175–179.
  Article CAS PubMed Google Scholar
• Walsh D, Rybicki L (2006). Symptom clustering in advanced cancer. Support Care Cancer 14: 831–836.
  Article PubMed Google Scholar
• Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM et al (2006). Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 24: 4485–4491.
  Article PubMed Google Scholar
• Weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann H et al (2006). Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 55: 1624–1630.
  Article CAS PubMed PubMed Central Google Scholar
• Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S (2003). Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29: 241–252.
  Article CAS PubMed Google Scholar
• Wichers MC, Koek GH, Robaeys G, Praamstra AJ, Maes M (2005). Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol Med 35: 433–441.
  Article CAS PubMed Google Scholar
• Wilkie MJ, Smith G, Day RK, Matthews K, Smith D, Blackwood D et al (2009). Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 9: 61–70.
  Article CAS PubMed Google Scholar
• Williams GW, Barton GM, White AA, Won H (1976). Cluster analysis applied to symptom ratings of psychiatric patients: an evaluation of its predictive ability. Br J Psychiatry 129: 178–185.
  Article CAS PubMed Google Scholar
• Yates WR, Gleason O (1998). Hepatitis C and depression. Depress Anxiety 7: 188–193.
  Article CAS PubMed Google Scholar
• Yonkers KA, Samson J (2000). Mood disorders measures. In: Rush AJ, Pincus HA, First MB, et al (eds) Handbook of Psychiatric Measures. American Psychiatric Association: Washington, DC. pp 515–549.
  Google Scholar
• Yoon JC, Crane PK, Ciechanowski PS, Harrington RD, Kitahata MM, Crane HM (2011). Somatic symptoms and the association between hepatitis C infection and depression in HIV-infected patients. AIDS Care 23: 1208–1218.
  Article PubMed PubMed Central Google Scholar
• Yoshida K, Alagbe O, Wang X, Woolwine B, Thornbury M, Raison CL et al (2005). Promoter polymorphisms of the interferon-alpha receptor gene and development of interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 52: 55–61.
  Article CAS PubMed Google Scholar
• Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM (2000). Hepatitis C, interferon alfa, and depression. Hepatology 31: 1207–1211.
  Article CAS PubMed Google Scholar